ClinicalTrials.gg
Not yet recruitingNCT06183450ACAVUpdated Dec 27, 2023

Hearing and Cognition in Aging Adults

An observational study in Presbycusis, sponsored by University Hospital, Toulouse. Not yet recruiting at 1 site in France. Open to participants aged 45 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-27.

Sponsored by University Hospital, Toulouse · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
262
Ages
45 Years to 50 Years
Sex
All
01

Study summary

This cohort study is expected to provide valuable insights into the complex interplay between auditory and cognitive functions and how they change over time. The results of this study will have important implications for the prevention, diagnosis, and treatment of age-related hearing and cognitive disorders

Read the detailed description

The aim of the study is to identify the early perceptual and cognitive alterations related to age-related hearing loss or presbycusis, establish a correlation between the degree of hearing loss and the deterioration of cognitive functions, and examine the effectiveness of hearing loss management in reversing observed cognitive impairments. This project has the potential to shed light on the importance of early detection of hearing impairments in preventing cognitive decline. The data collected from this cohort, rigorously assessed for both auditory and cognitive functions, could serve as the basis for several high-level scientific investigations.

02

Conditions studied

  • Presbycusis

Keywords

  • presbycusis
  • aging
  • cognitive decline
  • speech in noise
  • sound localisation
  • hearing loss
03

In context

Presbycusis

66 studies on the registry are indexed under Presbycusis; 21 are open to participants now.

This study's planned enrollment of 262 is above the median of 123 across 20 observational studies indexed under Presbycusis.

Browse Presbycusis studies →

Lead sponsor

University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Adult normal hearing subjects aged between 45 and 50 years old.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Normal hearing (Pure Tone Audiometry \< or = 20 dB)
  • Residency in one of the three neighborhoods :
  • Affiliation with a social security system

Exclusion criteria

Exclusion Criteria:

  • Individuals under guardianship, trusteeship or curators
  • History of neurological pathologies
  • Taking of psychotropic medication.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
262 participants (estimated)
Patient registry
No

Groups and cohorts

  • hearing subject

    Adult normal hearing subjects, evaluated annually for 5 years,

    Diagnostic Test: auditory level · Diagnostic Test: cognitive level · Diagnostic Test: quality of life level

Interventions

  • Diagnostic testauditory level

    * Evaluation of auditory thresholds through audiometric tests. * Evaluation of speech comprehension in noise through a vocal audiometry test in noise (FraMatrix). * Evaluation of spatial auditory behavior and spatial precision using a spatial discrimination test (Minimum Audible Angle) and a static sound localization test in virtual reality.

  • Diagnostic testcognitive level

    * Evaluation of attention and short-term memory functions with verbal and non-verbal tasks: Digit Span Test and Reading Span Test. * Evaluation of inhibition capacities using the Stroop Test. * Evaluation of executive functions, visual attention, reasoning, and mental arithmetic using the Raven's Matrix test.

  • Diagnostic testquality of life level

    - Evaluation of quality of live level via Speech, Spatial and Qualities of Hearing Scale (SSQ-12) and EuroQol-5D questionnaires.

06

What researchers measure

Primary outcomes

  1. Pure-ton audiometry

    Pure-tone audiometry will be evaluated by collecting the threshold in air and bone conduction for both ears on each frequency tested (125-250-500-1000-2000-4000 and 8000 Hz), as well as the average hearing loss (MAP ) on all five frequencies.

    Time frame: 5 years

07

Study locations

1 site
  • Ecole d'audioprothèse
    Cahors, France
    • Mariam ALZAHER, Dr · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06183450
Responsible party
Sponsor
First posted
Dec 27, 2023
Start date
Jan 2024 (estimated)
Primary completion
Jan 2033 (estimated)
Completion
Jan 2033 (estimated)
Last update
Dec 27, 2023

Study contacts

Mathieu Marx, Pr
Contact
marx.m@chu-toulouse.fr
05 61 77 77 04 ext. +33
Mariam ALZAHER, Dr
Contact
mariam.alzaher@cnrs.fr
Mathieu Marx, Pr
principal investigator · CHU Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion